Gan & Lee Pharmaceuticals Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100003ZH1
CNY
59.15
-1.07 (-1.78%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Mar'26
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Net Sales
878.11
1,005.11
980.24
1,081.93
975.80
791.49
930.11
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
878.11
1,005.11
980.24
1,081.93
975.80
791.49
930.11
Raw Material Cost
223.40
288.58
270.25
288.58
255.52
243.68
234.55
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Selling and Distribution Expenses
326.75
438.91
366.96
377.78
382.26
384.82
389.10
Other Expenses
12.80
22.21
12.64
12.33
11.96
12.61
12.55
Total Expenditure (Excl Depreciation)
678.19
949.63
763.58
789.64
757.43
754.64
749.16
Operating Profit (PBDIT) excl Other Income
199.89999999999998
55.5
216.70000000000002
292.3
218.4
36.9
181
Other Income
19.57
294.25
20.15
29.94
95.03
56.89
35.83
Operating Profit (PBDIT)
205.91
383.18
308.42
384.42
385.16
145.12
276.03
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Exceptional Items
6.73
1.75
7.10
17.97
46.99
-11.29
13.78
Gross Profit (PBDT)
654.71
716.53
709.99
793.35
720.28
547.81
695.56
Depreciation
0.00
80.83
80.83
71.76
71.76
67.05
67.05
Profit Before Tax
212.64
304.10
234.69
330.63
360.39
66.78
222.75
Tax
20.18
-21.15
20.03
38.87
48.47
-40.62
14.39
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
192.49
325.24
214.66
291.76
311.92
107.40
208.36
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
192.49
325.24
214.66
291.76
311.92
107.40
208.36
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
-0.02
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
192.46
325.24
214.66
291.76
311.92
107.40
208.36
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
11,826.16
11,628.47
11,282.39
10,965.23
11,312.12
11,054.47
11,206.86
Earnings per share (EPS)
0.33
0.55
0.37
0.49
0.53
0.18
0.35
Diluted Earnings per share
0.33
0.55
0.37
0.49
0.53
0.18
0.35
Operating Profit Margin (Excl OI)
21.22%
0.81%
21.16%
26.13%
22.38%
2.68%
18.62%
Gross Profit Margin
24.22%
38.3%
32.19%
37.19%
44.29%
16.91%
31.16%
PAT Margin
21.92%
32.36%
21.9%
26.97%
31.97%
13.57%
22.4%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Mar 2026 is -12.64% vs 2.54% in Dec 2025

stock-summary

Consolidate Net Profit

QoQ Growth in quarter ended Mar 2026 is -40.81% vs 51.47% in Dec 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is 109.56% vs -69.16% in Dec 2025

stock-summary

Interest

No Interest in the last few periods

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

Compare Quarterly Results Of Gan & Lee Pharmaceuticals Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
878.11
0
878.11
Other Operating Income
0.00
0.00
0.00
Total Operating income
878.11
0
878.11
Raw Material Cost
223.40
0
223.40
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
0.00
0
0.00
Selling and Distribution Expenses
326.75
0
326.75
Other Expenses
12.80
0.00
12.80
Total Expenditure (Excl Depreciation)
678.19
0
678.19
Operating Profit (PBDIT) excl Other Income
199.92
0.00
199.92
Other Income
19.57
0
19.57
Operating Profit (PBDIT)
205.91
0
205.91
Interest
0.00
0
0.00
Exceptional Items
6.73
0
6.73
Gross Profit (PBDT)
654.71
0
654.71
Depreciation
0.00
0
0.00
Profit Before Tax
212.64
0
212.64
Tax
20.18
0
20.18
Provisions and contingencies
0
0
0.00
Profit After Tax
192.49
0
192.49
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
192.49
0
192.49
Share in Profit of Associates
0
0
0.00
Minority Interest
-0.02
0
-0.02
Other related items
0.00
0.00
0.00
Consolidated Net Profit
192.46
0
192.46
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
11,826.16
0
11,826.16
Earnings per share (EPS)
0.33
0
0.33
Diluted Earnings per share
0.33
0
0.33
Operating Profit Margin (Excl OI)
21.22%
0%
0.00
21.22%
Gross Profit Margin
24.22%
0%
0.00
24.22%
PAT Margin
21.92%
0%
0.00
21.92%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 87.81 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is -12.64% vs 2.54% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is -10.01% vs 74.16% in Mar 2025

Quarterly - Consolidate Net Profit
Consolidate Net Profit 19.25 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is -40.81% vs 51.47% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is -38.28% vs 224.90% in Mar 2025

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 18.63 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 109.56% vs -69.16% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is -35.78% vs 376.35% in Mar 2025

Quarterly - Interest
Markets Mojo
No Interest in the last few periods
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 21.22%
in Mar 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 has fallen from Mar 2025